MKMurat Çağlar Karataş

Murat Çağlar Karataş

*This is an algorithmically generated author record based on publicly available information.

Murat Çağlar Karataş has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Etiological Spectrum of Primary Ovarian Insufficiency in a Group of Children and Adolescents: A Tertiary Single-Center Experience

    by Murat Çağlar Karataş, Özge Köprülü, Tayfun Cinleti, Özge Özer Kaya, Sezer Acar, Fatma Yavuzyılmaz Şimşek, FeyzaAltunbaş Yalabık, Kadri Murat Erdoğan, Tuba Hilkay Karapınar, İbrahim Mert Erbaş, et al.

  • Impact of continuous glucose monitoring on fear of hypoglycemia and quality of life in children and adolescents with type 1 diabetes

    by Özge Köprülü, Murat Çağlar Karataş, Sevgi Akbel, Fatma Yavuzyılmaz Şimşek, İbrahim Mert Erbaş, Özlem Nalbantoğlu, Hüseyin Anıl Korkmaz, Behzat Özkan

    Objectives: This study aimed to evaluate changes in fear of hypoglycemia (FOH) and quality of life (QoL) following at least six months of continuous glucose monitoring (CGM) use in the same cohort with type 1 diabetes mellitus (T1DM). Methods: This was a prospective, observational study including first-time CGM users. Auxologic, laboratory, and CGM data was collected. All participants were asked to complete the validated Turkish versions of the Pediatric Quality of Life Inventory (PedsQL) 3.0 Diabetes Module for both children and parents; the quality of life for youth scale for adolescents; children’s hypoglycemia index (CHI). Results: When pre- and post-CGM scores were compared, the mean total CHI score significantly decreased (p=0.018). Among the subscales, significant reductions were also observed in the “specific situations” (p=0.044) and “behavior scales” (p=0.025) subscales, whereas the “general fears” did not show a significant change (p=0.396). In PedsQL forms, there were no statistically significant differences between pre- and post-CGM total or subscale scores. CGM metrics were also compared between participants who showed improvement in FOH and/or QoL and those who did not. Participants with improvement in FOH had significantly higher sensor active use percentages compared to those without improvement (98.95 vs. 93.0 %, p=0.039). Conclusions: This study’s ability to assess pre- and post-CGM outcomes in the same patients highlights its clinical significance. Our findings suggest that using CGM in children and adolescents with T1DM is associated with a reduction in FOH.


  • Open Access

    Risk of Diabetes-Specific Eating Disorders in Children with Type 1 Diabetes Mellitus Using Continuous Subcutaneous Insulin Infusion: A CGM-Based Cross-Sectional Study

    by Özge Köprülü, Hülya Tan, İbrahim Mert Erbaş, Fatma Yavuzyılmaz Şimşek, Nilüfer Uyar, Murat Çağlar Karataş, Özlem Nalbantoğlu, Hüseyin Anıl Korkmaz, Behzat Özkan

    Background and Objectives: Eating disorders are one of the most widespread health concerns, mainly among adolescents. Children and adolescents with type 1 diabetes mellitus (T1DM) have been reported to have a high prevalence of eating disorders. The aim of our study is to evaluate the risk of diabetes-specific eating disorders in children with T1DM using continuous subcutaneous insulin infusion (CSII), with real-time glycemic data from continuous glucose monitoring (CGM). Materials and Methods: Sixty-four patients (aged 7–18 years) completed the Diabetes Eating Problem Survey-Revised (DEPS-R). The DEPS-R is a diabetes-specific self-report questionnaire to assess diabetes-specific compensatory behaviors. Auxological findings, sex, age, age at diagnosis, hemoglobin A1c (HbA1c) levels, and all CGM data were obtained from their medical records. Results: Although the median DEPS-R score was higher in children and adolescents using CSII compared to those using multiple daily injections (MDIs) (14 vs. 11), the difference was not statistically significant (p = 0.302). The risk of diabetes-specific eating disorders was identified in six patients (30%) using CSII and in nine patients (20.4%) using multiple daily injections (p = 0.403). Interestingly, in the subgroup with poor glycemic control (HbA1c > 9%), DEPS-R scores were significantly lower among those using CSII compared to the MDI group. Pearson correlation analysis demonstrated positive associations between DEPS-R scores and diabetes duration, weight SDS, body mass index (BMI), BMI SDS, HbA1c, mean glucose, Glucose Management Indicator (GMI), time above range (TAR) (very high), and coefficient of variation (CV), while a moderate negative correlation was observed with time in range (TIR). Conclusions: This study showed that the treatment of CSII had a beneficial effect on the risk of eating disorders in patients with poor glycemic control. As well, from this perspective, CSII maintains its status as a potentially beneficial therapeutic approach in diabetes management.